首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

2050792

曲妥珠單抗美坦新市場：依適應症、劑型、年齡層、最終用戶、通路及地區分類

Trastuzumab Emtansine Market, By Indication, By Strength, By Age Group, By End User, By Distribution Channel, By Geography

出版日期: 2026年03月10日 | 出版商:

Coherent Market Insights | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，曲妥珠單抗-美坦新市場規模將達到 27.7 億美元，到 2033 年將達到 50.2 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 8.9%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	27.7億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	8.90%	2033年市場規模預測：	520億美元

全球曲妥珠單抗-美坦新市場是腫瘤治療領域的關鍵細分市場，專注於用於治療HER2陽性乳癌的創新抗體藥物複合體（ADC）。曲妥珠單抗-美坦新結合了曲妥珠單抗的靶向特異性和美坦新素的細胞毒性，實現了精準醫療，可將化療直接遞送至癌細胞，同時最大限度地降低全身毒性。這項治療方法進展徹底改變了HER2陽性轉移性乳癌患者的治療模式，尤其適用於先前接受過曲妥珠單抗或紫杉烷類藥物治療的患者。

該市場涵蓋眾多相關人員，包括製藥企業、醫療服務提供者、監管機構和患者權益組織，他們都為這種救命治療方法的研發和普及做出了貢獻。隨著個人化醫療在腫瘤學領域日益重要，曲妥珠單抗-美坦新體現了治療性介入手段朝向更具標靶性和有效性的方向發展。全球市場的動態受到多種因素的影響，例如乳癌發病率上升、HER2檢測意識增強、新興市場醫療基礎設施不斷完善，以及正在進行的聯合治療和適應症拓展臨床研究，這些因素共同推動了該市場的發展，使其成為整個腫瘤藥物領域的重要組成部分。

市場動態

全球曲妥珠單抗-美坦新市場受多種強勁市場促進因素的推動，持續在全球醫療保健體系中擴張。其中一個關鍵促進因素是HER2陽性乳癌在全球持續成長的發生率，影響著全球約20-25%的乳癌患者，形成了一個龐大的標靶治療需求群體。診斷能力的提升和HER2檢測方案的廣泛應用顯著改善了患者的識別和治療方法選擇，直接促進了市場成長。與傳統化療方案相比，曲妥珠單抗-美坦新在領先的臨床試驗中展現出更優的療效，包括更長的無無惡化生存期和總生存期，這持續推動著醫生對該藥的接受度和患者的需求。

然而，該市場面臨阻礙其廣泛應用和普及的重大挑戰。曲妥珠單抗-美坦新療法的極高成本（通常每位患者每年超過10萬美元）對醫療系統、保險公司和患者構成了巨大的經濟障礙，尤其是在醫療預算有限的開發中國家。嚴格的監管核准流程和複雜的生產要求也加劇了市場准入障礙和供應鏈挑戰。此外，潛在的副作用，例如血小板減少性疾病、肝毒性和心臟功能障礙，可能會限制其治療適應症，並需要對患者進行密切監測。儘管有這些挑戰，但透過拓展其在轉移性乳癌以外的適應症，例如輔助性治療以及其他HER2陽性惡性腫瘤（如胃癌）的應用，仍存在著巨大的機會。雖然生物相似藥的開發可以降低成本並擴大市場進入，但與免疫療法和其他標靶治療的聯合治療策略有望改善治療效果，並擴大不同患者群體的市場覆蓋範圍。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並說明了該市場極具吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究基於以下參數分析了全球曲妥珠單抗-美坦新市場的主要參與者：公司亮點、產品系列、關鍵亮點、財務表現和策略。
本報告中的見解將使企業負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球曲妥珠單抗美坦新市場報告旨在為行業內的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過分析全球曲妥珠單抗美坦新市場的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第10章競爭格局

Genentech Inc.
Zydus Cadila
Formosa Pharmaceuticals
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

第11章分析師建議

機會分析
分析師意見
Coherent Opportunity Map

第12章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI8416

Trastuzumab Emtansine Market is estimated to be valued at USD 2.77 Bn in 2026 and is expected to reach USD 5.02 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.9% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 2.77 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.90%	2033 Value Projection:	USD 5.02 Bn

The global trastuzumab emtansine market represents a critical segment within the oncology therapeutics landscape, focusing on an innovative antibody-drug conjugate (ADC) designed to treat HER2-positive breast cancer. Trastuzumab emtansine combines the targeted specificity of trastuzumab with the cytotoxic potency of emtansine, creating a precision medicine approach that delivers chemotherapy directly to cancer cells while minimizing systemic toxicity. This therapeutic advancement has revolutionized treatment paradigms for patients with HER2-positive metastatic breast cancer, particularly those who have previously received trastuzumab and taxane-based therapies.

The market encompasses various stakeholders including pharmaceutical manufacturers, healthcare providers, regulatory bodies, and patient advocacy groups, all contributing to the development and accessibility of this life-saving treatment. As personalized medicine continues to gain prominence in oncology, trastuzumab emtansine exemplifies the evolution toward more targeted, effective therapeutic interventions. The global market dynamics are influenced by factors such as increasing breast cancer incidence rates, growing awareness of HER2 testing, expanding healthcare infrastructure in emerging markets, and ongoing clinical research exploring combination therapies and expanded indications, positioning this market as a significant contributor to the broader oncology pharmaceutical sector.

Market Dynamics

The global trastuzumab emtansine market is propelled by several robust drivers that continue to fuel its expansion across international healthcare systems. The primary driver remains the increasing global incidence of HER2-positive breast cancer, affecting approximately 20-25% of all breast cancer patients worldwide, creating a substantial patient population requiring targeted therapeutic interventions. Enhanced diagnostic capabilities and widespread implementation of HER2 testing protocols have significantly improved patient identification and treatment selection, directly contributing to market growth. The superior efficacy profile of trastuzumab emtansine compared to conventional chemotherapy regimens, demonstrated through pivotal clinical trials showing improved progression-free survival and overall survival rates, continues to drive physician adoption and patient demand.

However, the market faces considerable restraints that challenge widespread accessibility and adoption. The exceptionally high cost of trastuzumab emtansine treatment, often exceeding US$ 100,000 annually per patient, creates significant financial barriers for healthcare systems, insurance providers, and patients, particularly in developing economies with limited healthcare budgets. Stringent regulatory approval processes and complex manufacturing requirements contribute to market entry barriers and supply chain challenges. Additionally, potential adverse effects including thrombocytopenia, hepatotoxicity, and cardiac dysfunction require careful patient monitoring and may limit treatment eligibility. Despite these challenges, substantial opportunities emerge from expanding indications beyond metastatic breast cancer, including adjuvant settings and other HER2-positive malignancies such as gastric cancer. Biosimilar development presents opportunities for cost reduction and increased market access, while combination therapy strategies with immunotherapies and other targeted agents offer potential for enhanced therapeutic outcomes and market expansion in diverse patient populations.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global trastuzumab emtansine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Genentech Inc., Zydus Cadila, Formosa Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global trastuzumab emtansine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global trastuzumab emtansine market.

Market Segmentation

Indication Insights (Revenue, USD Bn, 2021 - 2033)
HER2-Positive, Metastatic Breast Cancer (MBC)
HER2-Positive Early Breast Cancer (EBC)
Strength Insights (Revenue, USD Bn, 2021 - 2033)
100 mg per vial
160 mg per vial
Age Group Insights (Revenue, USD Bn, 2021 - 2033)
Adult
Geriatric
End User Insights (Revenue, USD Bn, 2021 - 2033)
Hospitals
Cancer Treatment Centers
Specialty Clinics
Homecare Settings
Others (Research Institutes)
Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
Genentech Inc.
Zydus Cadila
Formosa Pharmaceuticals
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Trastuzumab Emtansine Market, By Indication
- Global Trastuzumab Emtansine Market, By Strength
- Global Trastuzumab Emtansine Market, By Age Group
- Global Trastuzumab Emtansine Market, By End User
- Global Trastuzumab Emtansine Market, By Distribution Channel
- Global Trastuzumab Emtansine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Trastuzumab Emtansine Market, By Indication, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
HER2-Positive, Metastatic Breast Cancer (MBC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
HER2-Positive Early Breast Cancer (EBC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Trastuzumab Emtansine Market, By Strength, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
100 mg per vial
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
160 mg per vial
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Trastuzumab Emtansine Market, By Age Group, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Trastuzumab Emtansine Market, By End User, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others (Research Institutes)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Trastuzumab Emtansine Market, By Distribution Channel, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Trastuzumab Emtansine Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Genentech Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Formosa Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Shanghai JMT-Bio Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies